metformin has been researched along with Hirsutism in 78 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Assessing the impact of adding combined oral contraceptives (COCs) or metformin to laser hair removal on the quality of life of polycystic ovarian syndrome (PCOS) patients with hirsutism." | 9.41 | Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. ( Dorgham, D; Dorgham, N; El-Kalioby, M; Haggag, H; Sharobim, A, 2021) |
| " To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome." | 9.30 | Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 9.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 9.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| " Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1." | 9.15 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 9.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| " Hirsutism was significantly better controlled in the metformin group (p = 0." | 9.14 | Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009) |
| "To compare hormone levels and clinical outcomes in patients with polycystic ovary syndrome (PCOS) after metformin therapy or laparoscopic ovarian diathermy (LOD) at 6 months follow-up." | 9.14 | Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. ( Asgari, Z; Ashrafinia, M; Eslami, B; Hosseini, R; Moini, A, 2009) |
| "The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial." | 9.14 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010) |
| "65 kg/m(2)) hirsute women with polycystic ovary syndrome and normal insulin sensitivity were treated with 850 mg metformin orally, three times daily, for 4 months." | 9.12 | Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. ( Baracat, EC; Halpern, A; Maciel, GA; Marcondes, JA; Yamashita, SA, 2007) |
| "Our data show that both metformin and rosiglitazone improve ovarian function and hirsutism in patients with PCOS." | 9.11 | The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M, 2005) |
| " There was a significant improvement in hirsutism at the end of the metformin phase compared with placebo: F-G score 15." | 9.10 | The effect of metformin on hirsutism in polycystic ovary syndrome. ( Gordon, D; Kelly, CJ, 2002) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "The object of this review was to compare metformin versus oral contraceptive pill (OCP) treatment in polycystic ovary syndrome." | 8.84 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007) |
| "Metformin administration resulted in significant decrease in the body weight, body mass index, hirsutism score, fasting and postprandial blood glucose, fasting serum insulin, HOMA index, sleep disturbances scale, and Epworth sleepiness scale compared to the untreated PCOS group." | 7.80 | Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. ( Abdelmotaleb, GS; Aly, MK; El-Sharkawy, AA; Kabel, AM, 2014) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills." | 7.77 | [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011) |
| "This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome." | 7.74 | The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 7.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 7.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance." | 6.71 | Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated." | 6.71 | Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003) |
| "Metformin and OCPs were similar in terms of impact on hirsutism." | 6.53 | Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016) |
| "Assessing the impact of adding combined oral contraceptives (COCs) or metformin to laser hair removal on the quality of life of polycystic ovarian syndrome (PCOS) patients with hirsutism." | 5.41 | Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. ( Dorgham, D; Dorgham, N; El-Kalioby, M; Haggag, H; Sharobim, A, 2021) |
| " To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome." | 5.30 | Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 5.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| " Additionally, novel cosmetic techniques like electrolysis, laser and use of topically applied eflornithine to tackle the most distressing feature of facial hirsutism associated with PCOS, non-pharmacological therapy like acupuncture and the role of herbal medicine in PCOS management have also been discussed." | 5.22 | Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. ( Ali, T; Amin, F; Ara, R; Bader, GN; Kareem, O; Malik, A; Mir, SA; Rashid, R, 2022) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| " They were treated with clomiphene citrate, metformin, or both (combination) for up to six cycles, and hirsutism evaluators were blinded to group assignment." | 5.16 | Altering hirsutism through ovulation induction in women with polycystic ovary syndrome. ( Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Gosman, GG; Huang, H; Legro, RS; McGovern, PG; Myers, ER; Nestler, JE; Roth, LW; Schlaff, WD; Steinkampf, MP; Zhang, H, 2012) |
| " Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1." | 5.15 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 5.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 5.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "To compare hormone levels and clinical outcomes in patients with polycystic ovary syndrome (PCOS) after metformin therapy or laparoscopic ovarian diathermy (LOD) at 6 months follow-up." | 5.14 | Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. ( Asgari, Z; Ashrafinia, M; Eslami, B; Hosseini, R; Moini, A, 2009) |
| " Hirsutism was significantly better controlled in the metformin group (p = 0." | 5.14 | Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009) |
| "The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial." | 5.14 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010) |
| "65 kg/m(2)) hirsute women with polycystic ovary syndrome and normal insulin sensitivity were treated with 850 mg metformin orally, three times daily, for 4 months." | 5.12 | Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. ( Baracat, EC; Halpern, A; Maciel, GA; Marcondes, JA; Yamashita, SA, 2007) |
| "Our data show that both metformin and rosiglitazone improve ovarian function and hirsutism in patients with PCOS." | 5.11 | The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M, 2005) |
| " There was a significant improvement in hirsutism at the end of the metformin phase compared with placebo: F-G score 15." | 5.10 | The effect of metformin on hirsutism in polycystic ovary syndrome. ( Gordon, D; Kelly, CJ, 2002) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: finasteride, flutamide, metformin, spironolactone, cyproterone acetate-ethinylestradiol (co-cyprindiol), interventions to achieve weight loss, ketoconazole, and mechanical hair removal." | 4.85 | PCOS. ( Cahill, D, 2009) |
| "The object of this review was to compare metformin versus oral contraceptive pill (OCP) treatment in polycystic ovary syndrome." | 4.84 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007) |
| " A significant reduction in hirsutism was found for flutamide, spironolactone, cyproterone acetate combined with an oral contraceptive, thiazolidinediones, oral contraceptive pills (OCPs), finasteride and metformin but not for placebo." | 4.84 | A systematic review of commonly used medical treatments for hirsutism in women. ( Conway, GS; Koulouri, O, 2008) |
| " When compared with metformin, spironolactone reduced hirsutism scores by 1." | 4.84 | Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. ( Cosma, M; Erwin, PJ; Flynn, DN; Kurtz, DM; Labella, ML; Montori, VM; Mullan, RJ; Swiglo, BA, 2008) |
| "Our objective was to conduct a systematic review and metaanalyses of randomized controlled trials of metformin or TZDs for the treatment of hirsutism." | 4.84 | Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. ( Cosma, M; Elamin, MB; Erwin, PJ; Flynn, DN; Kurtz, DM; Labella, ML; Montori, VM; Mullan, RJ; Swiglo, BA, 2008) |
| "Metformin administration resulted in significant decrease in the body weight, body mass index, hirsutism score, fasting and postprandial blood glucose, fasting serum insulin, HOMA index, sleep disturbances scale, and Epworth sleepiness scale compared to the untreated PCOS group." | 3.80 | Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. ( Abdelmotaleb, GS; Aly, MK; El-Sharkawy, AA; Kabel, AM, 2014) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills." | 3.77 | [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011) |
| "This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome." | 3.74 | The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 3.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 3.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated." | 2.71 | Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003) |
| "Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance." | 2.71 | Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "Metformin treatment was well tolerated and was accompanied by a marked drop in hirsutism score, insulin response to oral glucose tolerance test, free androgen index, and baseline testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate levels (all P < 0." | 2.69 | Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N; Valls, C, 2000) |
| "Metformin and OCPs were similar in terms of impact on hirsutism." | 2.53 | Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016) |
| "Hirsutism affects 5-25% women, and the condition is most often caused by polycystic ovary syndrome (PCOS)." | 2.53 | Endocrine and metabolic characteristics in polycystic ovary syndrome. ( Glintborg, D, 2016) |
| "Polycystic ovary syndrome is the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management]. ( Csenteri, OK; Gődény, S, 2015) |
| "Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015) |
| "Hirsutism is a common medical complaint among women of reproductive age, and it affects the majority of women with the polycystic ovary syndrome (PCOS)." | 2.50 | Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. ( Gambineri, A; Pasquali, R, 2014) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "Metformin was less effective than the OCP in improving menstrual pattern (Peto odds ratio (OR) 0." | 2.44 | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. ( Costello, M; Eden, J; Johnson, N; Shrestha, B; Sjoblom, P, 2007) |
| "Polycystic ovary syndrome is a multi-system endocrinopathy with long-term metabolic and cardiovascular health consequences." | 2.43 | Contemporary medical therapy for polycystic ovary syndrome. ( Domino, SE; Lanham, MS; Lebovic, DI, 2006) |
| "Hirsutism is the presence of excessive body hair in a male pattern distribution in a woman, and can affect up to 20% of women." | 1.91 | An evaluation of the available pharmacotherapy for the treatment of hirsutism. ( Asfour, L; Kazmi, A; Sinclair, R, 2023) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.28) | 18.2507 |
| 2000's | 30 (38.46) | 29.6817 |
| 2010's | 40 (51.28) | 24.3611 |
| 2020's | 7 (8.97) | 2.80 |
| Authors | Studies |
|---|---|
| Rashid, R | 1 |
| Mir, SA | 1 |
| Kareem, O | 1 |
| Ali, T | 1 |
| Ara, R | 1 |
| Malik, A | 1 |
| Amin, F | 1 |
| Bader, GN | 1 |
| Cui, YY | 1 |
| Jiajue, JRZ | 1 |
| Chen, MP | 1 |
| Lu, L | 1 |
| Yu, M | 1 |
| Wang, LJ | 1 |
| Asfour, L | 1 |
| Kazmi, A | 1 |
| Sinclair, R | 1 |
| Xiong, T | 1 |
| Fraison, E | 1 |
| Kolibianaki, E | 1 |
| Costello, MF | 2 |
| Venetis, C | 1 |
| Kostova, EB | 1 |
| Tang, Z | 1 |
| Guan, J | 1 |
| Mao, JH | 1 |
| Han, L | 1 |
| Zhang, JJ | 1 |
| Chen, R | 1 |
| Jiao, Z | 1 |
| Dorgham, N | 1 |
| Sharobim, A | 1 |
| Haggag, H | 1 |
| El-Kalioby, M | 1 |
| Dorgham, D | 1 |
| Torres-Zegarra, C | 1 |
| Sundararajan, D | 1 |
| Benson, J | 1 |
| Seagle, H | 1 |
| Witten, M | 1 |
| Walders-Abramson, N | 1 |
| Simon, SL | 1 |
| Huguelet, P | 1 |
| Nokoff, NJ | 1 |
| Cree-Green, M | 1 |
| Ibáñez, L | 6 |
| Del Río, L | 1 |
| Díaz, M | 3 |
| Sebastiani, G | 1 |
| Pozo, ÓJ | 1 |
| López-Bermejo, A | 3 |
| de Zegher, F | 6 |
| Morgante, G | 1 |
| Massaro, MG | 1 |
| Di Sabatino, A | 1 |
| Cappelli, V | 1 |
| De Leo, V | 1 |
| Alpañés, M | 1 |
| Álvarez-Blasco, F | 1 |
| Fernández-Durán, E | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 2 |
| Lepine, S | 1 |
| Jo, J | 1 |
| Metwally, M | 1 |
| Cheong, YC | 1 |
| Tiwari, N | 1 |
| Pasrija, S | 1 |
| Jain, S | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Pasquali, R | 2 |
| Gambineri, A | 2 |
| Gómez-Pérez, AM | 1 |
| Fernández-García, JC | 1 |
| Mancha Doblas, I | 1 |
| Tinahones, FJ | 1 |
| Ong, KK | 1 |
| Dunger, DB | 2 |
| Conway, G | 1 |
| Dewailly, D | 2 |
| Diamanti-Kandarakis, E | 2 |
| Franks, S | 1 |
| Kelestimur, F | 3 |
| Macut, D | 1 |
| Micic, D | 1 |
| Pfeifer, M | 1 |
| Pignatelli, D | 1 |
| Pugeat, M | 2 |
| Yildiz, B | 1 |
| El-Sharkawy, AA | 1 |
| Abdelmotaleb, GS | 1 |
| Aly, MK | 1 |
| Kabel, AM | 1 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Reynolds, RV | 1 |
| Powers, SE | 1 |
| Uliassi, NW | 1 |
| Sullivan, SD | 1 |
| Tuchman, LK | 1 |
| Mehra, R | 1 |
| Gomez-Lobo, V | 1 |
| Spritzer, PM | 2 |
| Motta, AB | 2 |
| Sir-Petermann, T | 1 |
| van Zuuren, EJ | 1 |
| Fedorowicz, Z | 1 |
| Carter, B | 1 |
| Pandis, N | 1 |
| Hecht Baldauff, N | 1 |
| Arslanian, S | 1 |
| Diri, H | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Unluhizarci, K | 1 |
| Tanriverdi, F | 1 |
| Karaca, Z | 1 |
| Goodman, NF | 1 |
| Cobin, RH | 1 |
| Futterweit, W | 1 |
| Glueck, JS | 1 |
| Legro, RS | 2 |
| Carmina, E | 1 |
| Gallego-Escuredo, JM | 1 |
| Villarroya, F | 1 |
| Gődény, S | 2 |
| Csenteri, OK | 2 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| de Courten, B | 1 |
| Misso, ML | 1 |
| Moran, LJ | 1 |
| Teede, HJ | 1 |
| Martins, WP | 1 |
| Glintborg, D | 1 |
| Al Khalifah, RA | 1 |
| Florez, ID | 1 |
| Dennis, B | 1 |
| Thabane, L | 1 |
| Bassilious, E | 1 |
| Kępczyńska-Nyk, A | 1 |
| Muszel, M | 1 |
| Radziszewski, M | 1 |
| Wocial, K | 1 |
| Rezvanian, H | 1 |
| Adibi, N | 1 |
| Siavash, M | 1 |
| Kachuei, A | 1 |
| Shojaee-Moradie, F | 1 |
| Asilian, A | 1 |
| Cahill, D | 1 |
| Ashrafinia, M | 1 |
| Hosseini, R | 1 |
| Moini, A | 1 |
| Eslami, B | 1 |
| Asgari, Z | 1 |
| Klein, F | 1 |
| Fux Otta, C | 1 |
| Wior, M | 1 |
| Iraci, GS | 1 |
| Kaplan, R | 1 |
| Torres, D | 1 |
| Gaido, MI | 1 |
| Wyse, EP | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Langmár, Z | 1 |
| Brodell, LA | 1 |
| Mercurio, MG | 1 |
| Petrányi, G | 2 |
| Zaoura-Petrányi, M | 1 |
| Marcos, MV | 2 |
| Oner, G | 1 |
| Muderris, II | 1 |
| Banaszewska, B | 1 |
| Pawelczyk, L | 1 |
| Spaczynski, RZ | 1 |
| Duleba, AJ | 1 |
| Raval, AD | 1 |
| Hunter, T | 1 |
| Stuckey, B | 1 |
| Hart, RJ | 1 |
| Du, Q | 1 |
| Wang, YJ | 1 |
| Yang, S | 1 |
| Wu, B | 1 |
| Han, P | 1 |
| Zhao, YY | 1 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ganie, MA | 1 |
| Ammini, AC | 1 |
| Roth, LW | 1 |
| Huang, H | 1 |
| Diamond, MP | 1 |
| Coutifaris, C | 1 |
| Carson, SA | 1 |
| Steinkampf, MP | 1 |
| Carr, BR | 1 |
| McGovern, PG | 1 |
| Cataldo, NA | 1 |
| Gosman, GG | 1 |
| Nestler, JE | 1 |
| Myers, ER | 1 |
| Zhang, H | 1 |
| Schlaff, WD | 1 |
| Kelly, CJ | 1 |
| Gordon, D | 1 |
| Awartani, KA | 1 |
| Cheung, AP | 1 |
| Quint, EH | 1 |
| Kazerooni, T | 1 |
| Dehghan-Kooshkghazi, M | 1 |
| Harborne, L | 1 |
| Fleming, R | 1 |
| Lyall, H | 1 |
| Sattar, N | 1 |
| Norman, J | 1 |
| Frank-Raue, K | 1 |
| Schulze, E | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Barbieri, RL | 1 |
| Gargiulo, AR | 1 |
| Sahin, Y | 1 |
| Ehrmann, DA | 1 |
| Al-Inany, H | 1 |
| Yilmaz, M | 2 |
| Karakoç, A | 2 |
| Törüner, FB | 1 |
| Cakir, N | 2 |
| Tiras, B | 2 |
| Ayvaz, G | 2 |
| Arslan, M | 2 |
| Biri, A | 1 |
| Törüner, F | 1 |
| Bingöl, B | 1 |
| Lanham, MS | 1 |
| Lebovic, DI | 1 |
| Domino, SE | 1 |
| Costello, M | 1 |
| Shrestha, B | 2 |
| Eden, J | 2 |
| Sjoblom, P | 2 |
| Johnson, N | 1 |
| Johnson, NP | 1 |
| Marcondes, JA | 1 |
| Yamashita, SA | 1 |
| Maciel, GA | 1 |
| Baracat, EC | 1 |
| Halpern, A | 1 |
| Homburg, R | 1 |
| Koulouri, O | 1 |
| Conway, GS | 1 |
| Swiglo, BA | 2 |
| Cosma, M | 2 |
| Flynn, DN | 2 |
| Kurtz, DM | 2 |
| Labella, ML | 2 |
| Mullan, RJ | 2 |
| Erwin, PJ | 2 |
| Montori, VM | 2 |
| Elamin, MB | 1 |
| Abbas, M | 1 |
| Gannon, M | 1 |
| Crave, JC | 1 |
| Fimbel, S | 1 |
| Lejeune, H | 1 |
| Cugnardey, N | 1 |
| Déchaud, H | 1 |
| Valls, C | 1 |
| Potau, N | 1 |
| Laboureau-Soares Barbosa, S | 1 |
| Rodien, P | 1 |
| Rohmer, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Gender Affirmative Treatment of Hypertrichosis With Intense Pulsed Light - Effect on Hair Reduction and Quality of Life[NCT05775328] | 39 participants (Anticipated) | Observational | 2023-12-01 | Not yet recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial[NCT00396513] | 0 participants | Interventional | 2005-09-30 | Recruiting | |||
| Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome[NCT00068861] | Phase 3 | 678 participants | Interventional | 2002-11-30 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272] | 128 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918] | 60 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471] | 36 participants (Anticipated) | Observational | 2012-12-06 | Active, not recruiting | |||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Pilot Study on the Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic[NCT05196568] | 100 participants (Anticipated) | Interventional | 2021-07-01 | Active, not recruiting | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
33 reviews available for metformin and Hirsutism
| Article | Year |
|---|---|
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.
Topics: Acupuncture; Anovulation; Eflornithine; Female; Herbal Medicine; Hirsutism; Humans; Hydroxymethylglu | 2022 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Acne Vulgaris; Contraceptives, Oral; Female; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase | 2023 |
Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis.
Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Female; Hirsutism; Humans; Hypoglycemic Agent | 2023 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Ovarian surgery for symptom relief in women with polycystic ovary syndrome.
Topics: Acne Vulgaris; Clomiphene; Female; Gonadotropins; Hirsutism; Humans; Laparoscopy; Letrozole; Menstru | 2017 |
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.
Topics: Androgen Antagonists; Androgens; Bariatric Surgery; Female; Hair Removal; Hirsutism; Humans; Metform | 2014 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
Interventions for hirsutism (excluding laser and photoepilation therapy alone).
Topics: 5-alpha Reductase Inhibitors; Adult; Androgen Antagonists; Body Mass Index; Contraceptive Agents, Fe | 2015 |
Optimal management of polycystic ovary syndrome in adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Diagnosis, Differential; Disease Management; Female; Hir | 2015 |
Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Female; Hirsutism; Hormones; Humans; Hyperan | 2015 |
[Evidence-based therapy of polycystic ovarian syndrome].
Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace | 2015 |
[Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management].
Topics: Biomarkers; Counseling; Dermatology; Diabetes Mellitus, Type 2; Disease Management; Endocrinology; E | 2015 |
Endocrine and metabolic characteristics in polycystic ovary syndrome.
Topics: Biomarkers; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic S | 2016 |
Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis.
Topics: Acne Vulgaris; Adolescent; Body Mass Index; Contraceptives, Oral; Female; Glucose Metabolism Disorde | 2016 |
PCOS.
Topics: Diabetes Mellitus, Type 2; Flutamide; Hair Removal; Hirsutism; Humans; Metformin; Polycystic Ovary S | 2009 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase | 2011 |
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
Metformin and polycystic ovary syndrome: a literature review.
Topics: Androgens; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Lipi | 2002 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab | 2004 |
Medical treatment regimens of hirsutism.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Enzyme Inhibitors; Ethinyl Estradiol; | 2004 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin | 2004 |
Contemporary medical therapy for polycystic ovary syndrome.
Topics: Acne Vulgaris; Adult; Clomiphene; Estrogen Antagonists; Female; Hirsutism; Humans; Hypoglycemic Agen | 2006 |
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Topics: Acne Vulgaris; Cardiovascular Diseases; Contraceptives, Oral, Combined; Endometrial Neoplasms; Femal | 2007 |
Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.
Topics: Acne Vulgaris; Adult; Cardiovascular Diseases; Contraceptives, Oral, Combined; Female; Hirsutism; Hu | 2007 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fem | 2008 |
A systematic review of commonly used medical treatments for hirsutism in women.
Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination | 2008 |
Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
Topics: Androgen Antagonists; Hirsutism; Humans; Metformin; Randomized Controlled Trials as Topic | 2008 |
Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
Topics: Androgen Antagonists; Drug Therapy, Combination; Hirsutism; Humans; Hypoglycemic Agents; Metformin; | 2008 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing | 2002 |
21 trials available for metformin and Hirsutism
| Article | Year |
|---|---|
Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients.
Topics: Administration, Oral; Adolescent; Adult; Combined Modality Therapy; Contraceptives, Oral, Combined; | 2021 |
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypo | 2017 |
Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Combined Modality Therapy; Exercise Therapy; Female; Glucose Tolerance Test; | 2019 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac | 2016 |
Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome.
Topics: Adult; Female; Hair Removal; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2009 |
Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Diathermy; Female; Fertility Agents, Female; Hirsutism; Humans; Hypoglycemic Agen | 2009 |
Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol; Double-Blind Method; Female; Follicle Stimulati | 2010 |
Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Topics: Adolescent; Child; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agen | 2011 |
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female; | 2011 |
Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.
Topics: Adult; C-Reactive Protein; Drug Therapy, Combination; Female; Hirsutism; Humans; Hydroxymethylglutar | 2011 |
Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2012 |
The effect of metformin on hirsutism in polycystic ovary syndrome.
Topics: Body Constitution; Body Height; Body Weight; Double-Blind Method; Female; Hair; Hirsutism; Humans; H | 2002 |
Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Topics: Acne Vulgaris; Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Fa | 2003 |
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; | 2003 |
The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Female; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insu | 2005 |
Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Body Weight; Female; Hirsutism; Hormones; Humans; Hypoglycemic Age | 2007 |
Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.
Topics: Androgens; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Composition; Cholesterol; Chol | 1995 |
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Topics: Adolescent; Adult; Blood Glucose; Female; Hirsutism; Hormones; Humans; Hyperandrogenism; Hyperinsuli | 2000 |
24 other studies available for metformin and Hirsutism
| Article | Year |
|---|---|
[The 495th case: young female-hyperandrogenemia-severe insulin resistance].
Topics: Acanthosis Nigricans; Adult; Diabetes Mellitus; Female; Hirsutism; Humans; Insulin; Insulin Resistan | 2022 |
An evaluation of the available pharmacotherapy for the treatment of hirsutism.
Topics: Androgen Antagonists; Female; Hair; Hirsutism; Humans; Hyperandrogenism; Male; Metformin | 2023 |
Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic.
Topics: Adolescent; Adult; Alopecia; Child; Female; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome; | 2021 |
[Liraglutide in polycystic ovary syndrome].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon-Like Peptide 1; Hirsutism; Humans | 2014 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire.
Topics: Adult; Androgens; Biomarkers; Clomiphene; Contraceptives, Oral; Diagnosis, Differential; Endocrinolo | 2014 |
Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome.
Topics: Adolescent; Blood Glucose; Body Mass Index; Body Weight; Child; Female; Hirsutism; Humans; Hypoglyce | 2014 |
Trends in standard workup performed by pediatric subspecialists for the diagnosis of adolescent polycystic ovary syndrome.
Topics: Adolescent; Adolescent Medicine; Androgens; Child; Contraceptives, Oral; Endocrinology; Female; Gyne | 2015 |
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Topics: Adolescent; Alopecia; Androgen Antagonists; Androgens; Anovulation; Diagnostic Techniques, Endocrine | 2015 |
Reply: Metformin for women with hyperandrogenic anovulation.
Topics: Anovulation; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2016 |
Metformin for women with hyperandrogenic anovulation.
Topics: Anovulation; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2016 |
[Woman 19-old with hirsutism, obesity and acanthosis nigricans].
Topics: Acanthosis Nigricans; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Ob | 2016 |
[Polycystic ovary syndrome. Diet helps control hormone chaos].
Topics: Acne Vulgaris; Adolescent; Adult; Androgens; Child; Combined Modality Therapy; Female; Hirsutism; Hu | 2009 |
Androgen excess in women: not just a cosmetic problem.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Female; Hirsutism; Humans; Hyperan | 2010 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe | 2010 |
[Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
Topics: Acne Vulgaris; Adult; Body Mass Index; Caloric Restriction; Case-Control Studies; Drug Administratio | 2011 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Hirsutism and adnexal masses in a teenager.
Topics: Abdominal Pain; Adolescent; Contraceptives, Oral, Combined; Diagnosis, Differential; Female; Hirsuti | 2002 |
[Hirsutism].
Topics: Adolescent; Adrenal Hyperplasia, Congenital; Adult; Androgen Antagonists; Anti-Inflammatory Agents; | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
[Treatment experience with metformin in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistan | 2005 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu | 2005 |
Hirsutism.
Topics: Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Female; Flutamide; Hirsutism; | 2006 |
The use of metformin as first line treatment in polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Body Mass Index; Clomiphene; Female; Follicle Stimulating Hormone; Hi | 2008 |